A share price of Prime Medicine Inc [PRME] is currently trading at $3.18, up 9.28%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PRME shares have gain 17.78% over the last week, with a monthly amount glided 20.45%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Prime Medicine Inc [NASDAQ: PRME] stock has seen the most recent analyst activity on December 10, 2024, when JMP Securities initiated its Mkt Outperform rating and assigned the stock a price target of $10. Previously, H.C. Wainwright started tracking the stock with Buy rating on May 20, 2024, and set its price target to $10. On May 16, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $10 on the stock. Chardan Capital Markets started tracking the stock assigning a Buy rating and suggested a price target of $17 on April 22, 2024. TD Cowen initiated its recommendation with a Buy. Wedbush started tracking with a Outperform rating for this stock on April 03, 2024, and assigned it a price target of $12. In a note dated January 16, 2024, Stifel downgraded an Hold rating on this stock and revised its target price from $18 to $9.
Prime Medicine Inc experienced fluctuations in its stock price throughout the past year between $2.56 and $9.77. Currently, Wall Street analysts expect the stock to reach $17.25 within the next 12 months. Prime Medicine Inc [NASDAQ: PRME] shares were valued at $3.18 at the most recent close of the market. An investor can expect a potential return of 442.45% based on the average PRME price forecast.
Analyzing the PRME fundamentals
Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -5.87%, Pretax Profit Margin comes in at -5.68%, and Net Profit Margin reading is -5.68%. To continue investigating profitability, this company’s Return on Assets is posted at -0.66, Equity is -1.15 and Total Capital is -0.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.96 points at the first support level, and at 2.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.32, and for the 2nd resistance point, it is at 3.46.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Prime Medicine Inc [NASDAQ:PRME] is 6.50. Also, the Quick Ratio is 6.50, while the Cash Ratio stands at 3.11. Considering the valuation of this stock, the price to sales ratio is 521.37, the price to book ratio is 2.20.
Transactions by insiders
Recent insider trading involved NELSEN ROBERT, Director, that happened on Feb 15 ’24 when 3.2 million shares were purchased. 10% Owner, ARCH Venture Partners XII, LLC completed a deal on Feb 15 ’24 to buy 3.2 million shares. Meanwhile, 10% Owner ARCH Venture Partners X, LLC bought 3.2 million shares on Feb 15 ’24.
